Prasugrel hydrochloride

"目录号: HY-15284A

GPCR/G Protein-

Prasugrel盐酸盐是血小板抑制剂,IC50为1.8 μM。

P2Y Receptor

相关产品

Suramin sodium salt-Clopidogrel hydrogen sulfate-Ticagrelor-MRS 2578-Prasugrel-AZD1283-N6-(4-Hydroxybenzyl)adenosine-Diquafosol tetrasodium-Denufosol tetrasodium-

生物活性

Description

Prasugrel hydrochloride is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel hydrochloride is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel hydrochloride reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel hydrochloride AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia;  Nausea; Epistaxis

Clinical Trial

NCT02212028

University of Florida

Coronary Artery Disease

October 2014

Phase 4

NCT01493999

University of Pecs

Acute Coronary Syndrome

September 2011

Phase 4

NCT01260584

Daiichi Sankyo Inc.

Coronary Artery Disease

November 2010

Phase 4

NCT01476696

Eli Lilly and Company-Daiichi Sankyo Inc.

Sickle Cell Disease

November 2011

Phase 2

NCT01560780

VA Office of Research and Development

Coronary Artery Bypass

February 1, 2013

Phase 3

NCT01115738

Eli Lilly and Company

Acute Coronary Syndrome

May 2010

Phase 2

NCT01014624

Daiichi Sankyo Inc.

Coronary Artery Disease

February 2010

Phase 4

NCT01201772

University of Florida

Coronary Artery Disease

August 2010

Phase 4

NCT01835353

University of Patras

Platelet Reactivity

June 2012

Phase 3

NCT01178099

Eli Lilly and Company-Daiichi Sankyo Co., Ltd.

Anemia, Sickle Cell

July 2010

Phase 1

NCT01852175

University of Florida

Coronary Artery Disease

January 2012

NCT01852214

University of Florida

Diabetes Mellitus-Coronary Artery Disease

February 2013

NCT01365221

Medstar Health Research Institute

Acute Coronary Syndrome

December 2010

Phase 4

NCT01531114

Gennaro Sardella-University of Roma La Sapienza

ST-Elevation Myocardial Infarction

May 2013

Phase 3

NCT01641510

Dong-A University

Acute Coronary Syndromes

October 2013

Phase 3

NCT01591317

Eli Lilly and Company

Healthy Volunteers

March 2009

Phase 1

NCT02070159

Dong-A University

Coronary Artery Disease

December 2011

Phase 3

NCT01465828

Gennaro Sardella-University of Roma La Sapienza

Acute Coronary Syndrome

October 2011

Phase 3

NCT02075125

Dong-A University

ST-Segment Elevation Myocardial Infarction

January 2014

Phase 3

NCT01778842

Gennaro Sardella-University of Roma La Sapienza

Coronary Artery Disease

March 2013

Phase 3

NCT01876797

Asan Medical Center

Healthy

July 2013

Phase 1

NCT01852019

The Medicines Company

Coronary Artery Disease

June 2013

Phase 2

NCT01430091

Eli Lilly and Company

Sickle Cell Disease

September 2011

Phase 1

NCT01951001

Gyeongsang National University Hospital

Acute Coronary Syndrome-Platelet Thrombus-Bleeding

July 2013

Phase 4

NCT02065479

University of Florida

Coronary Artery Disease

March 2014

Phase 4

NCT02808767

Faculty Hospital Kralovske Vinohrady

Myocardial Infarction-Angioplasty, Balloon, Coronary-Platelet Aggregation Inhibitors

January 2013

Phase 4

NCT00385944

Eli Lilly and Company-Daiichi Sankyo Inc.

Acute Coronary Syndrome

March 2007

Phase 2

NCT01304472

University of Patras

Coronary Artery Disease (CAD)

February 2011

Phase 3

NCT01790854

David Antoniucci-A.R. CARD Onlus Foundation-Careggi Hospital

Adverse Reaction to Antiplatelet Agent-Acute Coronary Syndrome

November 2012

Phase 4

NCT01609647

Dong-A University

Acute Coronary Syndrome

September 2012

Phase 3

NCT01789814

Tufts Medical Center

Coronary Artery Disease

July 2013

Phase 4

NCT01587651

Daiichi Sankyo Inc.-Eli Lilly and Company

Coronary Artery Disease

March 2012

Phase 4

NCT02016170

University of Florida

Coronary Artery Disease-Acute Coronary Syndrome

March 2014

NCT01155765

University of Patras

Hemodialysis-Chronic Renal Failure

May 2010

Phase 3

NCT01648790

Eli Lilly and Company-Daiichi Sankyo Inc.

Healthy Volunteers

July 2012

Phase 1

NCT01109784

University of Patras

Coronary Artery Disease (CAD)-Acute Coronary Syndrome (ACS)

April 2010

Phase 3

NCT02507323

Yochai Birnbaum-AstraZeneca-Baylor College of Medicine

Cardiovascular Disease

February 2016

Phase 2

NCT01463150

University of Patras

Platelet Reactivity

October 2011

Phase 4

NCT01456364

Deutsches Herzzentrum Muenchen

Coronary Heart Disease

September 2011

Phase 4

NCT01684813

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-Andaluz Health Service

Diabetes Mellitus Type II-Acute Coronary Syndrome

October 2012

Phase 4

NCT01167023

Eli Lilly and Company-Daiichi Sankyo Inc.

Sickle Cell Anemia

July 2010

Phase 2

NCT01463163

University of Patras

Platelet Reactivity

October 2011

Phase 4

NCT01794000

Eli Lilly and Company-Daiichi Sankyo Inc.

Sickle Cell Disease

April 2013

Phase 3

NCT02075268

Asan Medical Center

Healthy

January 2014

Phase 1

NCT02215993

Federal University of São Paulo

Acute Coronary Syndrome-Platelet Function

July 2013

Phase 4

NCT01543932

University of Roma La Sapienza

Coronary Artery Disease

July 2012

Phase 3

NCT02193971

Seoul National University Hospital-Boston Scientific Korea Co. Ltd-Dio-Terumo Corporation

Acute Coronary Syndrome

July 2014

Phase 4

NCT01338909

University of Patras

Myocardial Infarction

April 2011

Phase 3

NCT01869309

LifeBridge Health-AstraZeneca

Coronary Artery Disease

January 2014

Phase 4

NCT01774838

University of Cologne

Acute Coronary Syndrome-Unstable Angina

October 2014

Phase 3

NCT01944800

Deutsches Herzzentrum Muenchen-Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Acute Coronary Syndrome (ACS)

September 2013

推荐阅读更多精彩内容

  • "目录号: HY-15284B GPCR/G Protein- Prasugrel马来酸盐是是血小板抑制剂,IC5...
    莫小枫阅读 17评论 0 0
  • "目录号: HY-15284 GPCR/G Protein- Prasugrel是ADP受体抑制剂,能通过不可逆的...
    莫小枫阅读 43评论 0 0
  • "目录号: HY-15283 GPCR/G Protein- Clopidogrel是口服活性的P2Y12受体阻断...
    莫小枫阅读 33评论 0 0
  • "目录号: HY-13677 Cell Cycle/DNA DamageAutophagy- Mercaptopu...
    莫小枫阅读 61评论 0 0
  • "目录号: HY-14649 Metabolic Enzyme/ProteaseCell Cycle/DNA Da...
    莫小枫阅读 53评论 0 0